Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 18/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019378 | 0.88 | PTGIR (0.62) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL29019412 | 0.87 | PTGIR (0.73) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL6517586 | 0.86 | PTGIR (0.79) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL6517591 | 0.86 | PTGIR (0.79) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019377 | 0.84 | PTGIR (0.65) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019375 | 0.82 | PTGIR (0.69) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019388 | 0.82 | PTGIR (0.62) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019411 | 0.80 | PTGIR (0.62) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL23851382 | 0.80 | PTGIR (0.68) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019408 | 0.80 | PTGIR (0.68) | PTGIRPTGDRMGLLPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003123-B | Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders | 艾尼纳制药公司 | 2023-06-23 | — | — | CN | disclosed |